Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30521169 | 0.94 | HDAC4 (0.47) | HDAC4SMN1; SMN2NPSR1ALDH1A1GAA | |
| SCHEMBL25348517 | 0.94 | HDAC4 (0.47) | HDAC4SMN1; SMN2NPSR1ALDH1A1GAA | |
| SCHEMBL22832459 | 0.85 | HDAC4 (0.40) | HDAC4SMN1; SMN2NPSR1ALDH1A1GAA | |
| SCHEMBL25173605 | 0.84 | MAOB (0.48) | HDAC4SMN1; SMN2NPSR1ALDH1A1GAA | |
| SCHEMBL25173603 | 0.84 | MAOB (0.48) | HDAC4SMN1; SMN2NPSR1ALDH1A1GAA | |
| SCHEMBL30374633 | 0.84 | MAOB (0.48) | HDAC4SMN1; SMN2NPSR1ALDH1A1GAA | |
| SCHEMBL1492825 | 0.84 | AKR1C1 (0.59) | HDAC4SMN1; SMN2NPSR1ALDH1A1GAA | |
| SCHEMBL25183668 | 0.84 | HDAC4 (0.38) | HDAC4SMN1; SMN2NPSR1ALDH1A1GAA | |
| SCHEMBL28734886 | 0.84 | CHRNA1 (0.40) | HDAC4SMN1; SMN2NPSR1ALDH1A1GAA | |
| SCHEMBL29605345 | 0.84 | CHRNA1 (0.40) | HDAC4SMN1; SMN2NPSR1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028336-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4653436-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | GUANGZHOU YUFAN NANTU BIOTECHNOLOGIES CO., LTD (CN) | 2025-11-26 | — | — | EP | disclosed |
| EP-4558501-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024153240-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | 珠海宇繁生物科技有限责任公司 | 2024-07-25 | — | — | WO | disclosed |
| WO-2024020034-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020034-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-2280943-A1 | NEW SUBSTITUTED SPIROÝCYCLOALKYL-1,3'-INDOL¨-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | Almirall, S.A. (ES) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009124692-A1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | ALMIRALL, S.A. (ES) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028336-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | HDAC4 4082/4885SMN1; SMN2 1623/4885NPSR1 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.